Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: BMcV who wrote (3619)	8/20/1999 9:38:00 AM
From: Biomaven	Read Replies (2) \| Respond to of 10280

Bruce: Eisai and Janssen to Co-Market Aciphex(TM) (rabeprazole sodium), A New Proton Pump Inhibitor No, this isn't really cisapride related, although both categories are used to treat reflux. This is the third US ("me-too")entry in the category (proton pump acid blockers) in which omeprazole is the leader (and I think still the single-biggest selling drug in the world). A fourth (Lansoprazole) is I believe awaiting approval. SEPR has single-isomer ICE patents on at least two of the four (not omeprazole, which the originator is developing). Don't know who has the patent on the single isomer version of rabeprazole yet - wouldn't be surprised if SEPR ends up with it as well. This is a huge category of drugs, but my guess is that the ICE's aren't really substantial improvements over the underlying drugs, which are already pretty darn good (often once-a-day dosage). We'll see when Astra-Merck brings out the improved omeprazole. Peter